SBTX Silverback Therapeutics Inc.

Biotech Analyst Ratings

Latest News

1. 12 May 2022 Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

   Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.

   "In the first quarter of 2022, we have made significant progress in advancing the preclinical development of SBT8230, a first-in-class antibody-drug conjugate that we believe has the potential to drive functional cure in patients with chronic hepatitis B (cHBV) by eliciting a liver-localized anti-viral response," said Laura Shawver, Ph.D., chief executive…

   View Full Article
2. 31 March 2022 Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results

   - Strategic realignment to focus resources on SBT8230 for chronic hepatitis B virus (cHBV) and discovery pipeline by discontinuing SBT6050 and SBT6290 clinical oncology programs

   - On track to complete a Phase 1 regulatory submission for SBT8230 in the fourth quarter of 2022

   - Silverback to restructure workforce to support prioritized development, reduce operating expense, and extend cash runway

   - Estimated cash runway extended into the second half of 2026

   Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases…

   View Full Article
3. 24 February 2022 Silverback Therapeutics to Present at the 42nd Annual Cowen Healthcare Conference

   Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that members of the Silverback management team will participate in the 42^nd Annual Cowen Healthcare Conference from March 7-9, 2022.

   Laura Shawver, Ph.D., Silverback's Chief Executive Officer, will present a corporate overview on Wednesday, March 9^th, 2022, at 12:50 p.m. ET (9:50 a.m. PT). The live webcast of the presentation will be available on Silverback's Investor Relations website and a replay will be available for 30…

   View Full Article
4. 03 February 2022 Silverback Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

   Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that Silverback management will participate in the SVB Leerink 11^th Annual Global Healthcare Conference from February 14-18, 2022.

   Laura Shawver, Ph.D., Silverback's Chief Executive Officer, and Valerie Odegard, Ph.D., Silverback's President and Chief Scientific Officer, will participate in a fireside chat on Wednesday, February 16^th, 2022, at 1:00 PM ET (10:00 AM PT). The live webcast of the event will be available on Silverback's…

   View Full Article
5. 05 January 2022 Silverback Therapeutics to Participate in the H.C. Wainwright Bioconnect Conference

   Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that Silverback management will participate in the H.C. Wainwright Bioconnect Conference from January 10-13, 2022.

   Laura Shawver, Ph.D., Silverback's Chief Executive Officer, and Valerie Odegard, Ph.D., Silverback's President and Chief Scientific Officer, will provide a corporate overview which will be available on Silverback's Investor Relations website beginning on Monday, January 10, 2022, at 7:00 AM ET (4:00 AM PT).

   …

   View Full Article